We are live on ! Find out more
FLNA

Filana Therapeutics
FLNA

48 hedge funds and large institutions have $20.9M invested in Filana Therapeutics in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more call options, than puts

Call options by funds: $327K | Put options by funds: $147K

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 47 → 48 (+1)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

63% less capital invested

Capital invested by funds: $55.6M → $20.9M (-$34.8M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
48
Holders Change
+1
Holders Change %
+2.13%
% of All Funds
1.28%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
9
Increased
9
Reduced
11
Closed
8
Calls
$327K
Puts
$147K
Net Calls
+$180K
Net Calls Change
+$270K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$886K
2
VKH
Virtu KCG Holdings
New York
+$333K
3
BI
BVF Inc
California
+$304K
4
SIM
Spark Investment Management
New York
+$283K
5
Renaissance Technologies
Renaissance Technologies
New York
+$261K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$6.21M
2
NCM
Nantahala Capital Management
Connecticut
-$4.41M
3
GIM
Granahan Investment Management
Massachusetts
-$1.55M
4
TA
Teton Advisors
New York
-$192K
5
6CM
683 Capital Management
New York
-$178K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
Avalon Capital Management
California
$38K – – –
TSS
27
Two Sigma Securities
New York
$36K +$85.7K +5,170 New
TA
28
Teton Advisors
New York
$35K -$192K -11,570 -70%
Connor, Clark & Lunn Investment Management (CC&L)
29
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$31K -$5.2K -314 -7%
Bank of America
30
Bank of America
North Carolina
$29K -$4.37K -264 -6%
State Street
31
State Street
Massachusetts
$23K -$30.1K -1,817 -33%
Charles Schwab
32
Charles Schwab
California
$19K – – –
Group One Trading
33
Group One Trading
Illinois
$14K +$32.3K +1,948 New
Wells Fargo
34
Wells Fargo
California
$13K – – –
Wolverine Trading
35
Wolverine Trading
Illinois
$12K +$27.3K +1,648 New
Brown Advisory
36
Brown Advisory
Maryland
$12K +$27.9K +1,686 New
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$10K – – –
BA
38
BlackRock Advisors
Delaware
$9K – – –
BIM
39
BlackRock Investment Management
Delaware
$7K – – –
FANJ
40
Financial Architects (New Jersey)
New Jersey
$5K – – –
CG
41
Cutler Group
California
$4K +$9.94K +600 New
Morgan Stanley
42
Morgan Stanley
New York
$3K +$4.28K +258 +170%
Simplex Trading
43
Simplex Trading
Illinois
$2K +$6.74K +407 New
UBS Group
44
UBS Group
Switzerland
$1K – – –
Federated Hermes
45
Federated Hermes
Pennsylvania
$1K +$2.45K +148 New
SCM
46
Stonepine Capital Management
Oregon
– -$6.21M -405,411 Closed
GIM
47
Granahan Investment Management
Massachusetts
– -$1.55M -100,874 Closed
TRCT
48
Tower Research Capital (TRC)
New York
– -$47K -3,052 Closed
ARTA
49
A.R.T. Advisors
New York
– -$30K -1,975 Closed
Walleye Trading
50
Walleye Trading
New York
– -$3K -214 Closed
1
2
3

FLNA Hedge Fund Activity: Q3 2016 in Review

48 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q3 2016, worth a combined $20.9M — down 63% from $55.6M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new FLNA positions and 8 closed out — a net gain of 1 holder — while 9 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $886K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $6.21M sold.

  • 48 institutional investors held Filana Therapeutics (FLNA) as of Q3 2016, up from 47 in Q2 2016.
  • Funds reported $20.9M of Filana Therapeutics stock for Q3 2016, down 63% quarter-over-quarter.
  • 9 funds opened new Filana Therapeutics positions in Q3 2016 and 8 closed out, a net change of +1 holder.
  • The largest Filana Therapeutics buyer in Q3 2016 was Vanguard Group, an estimated $886K added.
  • The largest Filana Therapeutics seller in Q3 2016 was Stonepine Capital Management, an estimated $6.21M sold.

Based on aggregated 13F filings for Q3 2016.